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ABSTRACT
Background
Hepatitis C virus (HCV)-specific T cell responses are critical for spontaneous resolution of HCV
viremia. Here we examined the effect of a lymphotropic virus, HIV-1, on the ability of coinfected
patients to maintain spontaneous control of HCV infection.
Methods and Findings
We measured T cell responsiveness by lymphoproliferation and interferon-c ELISPOT in a
large cohort of HCV-infected individuals with and without HIV infection. Among 47 HCV/HIV-1-
coinfected individuals, spontaneous control of HCV was associated with more frequent HCV-
specific lymphoproliferative (LP) responses (35%) compared to coinfected persons who
exhibited chronic HCV viremia (7%, p ¼ 0.016), but less frequent compared to HCV controllers
who were not HIV infected (86%, p ¼ 0.003). Preservation of HCV-specific LP responses in
coinfected individuals was associated with a higher nadir CD4 count (r
2¼0.45, p , 0.001) and
the presence and magnitude of the HCV-specific CD8
þT cell interferon-c response (p¼0.0014).
During long-term follow-up, recurrence of HCV viremia occurred in six of 25 coinfected
individuals with prior control of HCV, but in 0 of 16 HIV-1-negative HCV controllers (p¼0.03, log
rank test). In these six individuals with recurrent HCV viremia, the magnitude of HCV viremia
following recurrence inversely correlated with the CD4 count at time of breakthrough (r ¼
 0.94, p ¼ 0.017).
Conclusions
These results indicate that HIV infection impairs the immune response to HCV—including in
persons who have cleared HCV infection—and that HIV-1-infected individuals with sponta-
neous control of HCV remain at significant risk for a second episode of HCV viremia. These
findings highlight the need for repeat viral RNA testing of apparent controllers of HCV infection
in the setting of HIV-1 coinfection and provide a possible explanation for the higher rate of HCV
persistence observed in this population.
The Editors’ Summary of this article follows the references.
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Hepatitis C virus (HCV) infection is associated with
persistence of viremia in the majority of infected persons,
characterized by high plasma viral RNA titers with or without
progressive liver disease. A minority of individuals establish
long-term viral control and thereby do not experience disease
progression, and spontaneous viral control is associated with
broad and vigorous CD4
þT cell responses [1–3], which endure
in the majority of persons [4]. In the United States and other
countries, there is an increasing recognition of coinfection
with HCV as a major problem in persons infected with HIV-1
[5]. Since the principal targets of HIV-1 infection are CD4
þ T
lymphocytes, two crucial questions are how infection with
HIV impacts CD4
þT cell responses to pathogens such as HCV,
and how this affects immune control of HCV infection.
For many acute viral infections, successful control is
predicated on the generation and maintenance of long-
lasting speciﬁc memory CD4
þ T cells, which support the
production of antibodies and the function of speciﬁc CD8
þ T
cells [6–9]. A rapidly growing body of evidence indicates that
CD4
þ T cell responses represent a critical component of a
successful immune response against HCV [10]. During the
acute phase of HCV infection, the breadth of this response
correlates with early control [3,11]. After successful clearance,
CD4
þ T lymphocytes that proliferate in response to recog-
nition of viral antigen are found in 64%–79% of spontaneous
controllers [4,12], target multiple epitopes [13,14], and can
outlast measurable humoral responses [4]. Recent CD4
þT cell
depletion experiments in HCV-infected chimpanzees re-
vealed the importance of these lymphocytes for the support
of functional CD8
þ T cell responses and the control of
viremia [7]. In humans, CD4
þ T cell depletion due to HIV is
associated with declining levels of functional CD8
þ T cells
speciﬁc for HCV [9]. The above evidence suggests a critical
role of virus-speciﬁc CD4
þ T cells in HCV control.
Thus far, studies of the impact of HIV infection on HCV-
speciﬁc CD4
þ T cells have focused on persons with chronic
HCV viremia [15–17]. The livers of HCV/HIV-coinfected
individuals are depleted of total intrahepatic CD4
þ T cells
[18], correlating with the low levels of antigen-speciﬁc CD4
þT
cell responsiveness within intrahepatic lymphocytes, even
after long-term culture with interleukin-2 (IL-2) [17]. Anal-
yses of peripheral blood in coinfected persons have similarly
revealed a paucity of CD4
þ T cell lymphocyte responses
against HCV, whether measuring interferon-c (IFN-c) secre-
tion [19,20] or proliferative capacity [15].
In this study, we focused on persons who are spontaneous
controllers of HCV infection but are coinfected with HIV-1.
We recruited a large cohort of HIVþ and HIV  participants,
including 47 participants exhibiting evidence of spontaneous
control of HCV, determined the effects of HIV-induced T cell
depletion on CD4
þ and CD8
þ T cell responsiveness to both
HIV-1 and HCV, and examined the durability of spontaneous
control of HCV in the setting of HIV-1 coinfection.
Methods
Study Population
Participants were recruited from clinics of the Infectious
Disease Division and Gastrointestinal Unit at Massachusetts
General Hospital and Lemuel Shattuck Hospital, both in
Boston, Massachusetts, United States. Participants gave
written informed consent under protocols approved by the
respective Institutional Review Boards and compliant with
guidelines of the Declaration of Helsinki regarding protec-
tion of human subjects. Participants who had received prior
interferon-based treatment for chronic HCV were excluded;
therefore, HCV viral RNA levels represent the natural
outcome of infection. In total, 94 participants were
recruited who demonstrated HCV antibody by enzyme
immunoassay, including 30 consecutively enrolled HIVþ/
HCVþ persons with HCV control, deﬁned below. CD8
þ T
cell responses were reported in a separate study for the ﬁrst
19 participants [9]. Nadir CD4
þ T cell counts, deﬁned as the
historically lowest measured CD4
þ T cell count, were
determined via chart review; this information was unavail-
able for four participants. As one control group, 30 HIVþ
participants with detectable HCV RNA were analyzed. In
addition, 34 HCV-monoinfected participants, including 17
viremic participants and 17 controllers, were studied. All
participants were analyzed after the early/acute phase of
either HCV or HIV-1 infection (deﬁned as .1 y from date
of infection).
Viral RNA Testing
Plasma HCV and HIV viral RNA titers were measured using
the Cobas Amplicor Monitor assay 2.0 with a detection limit
of 400 HIV-1 RNA copies/ml and 600 (2.8 log) HCV IU/ml
(Roche Molecular Systems [http://www.roche-diagnostics.us]).
Qualitative HCV viral RNA assays with a detection limit of 60
(1.8 log) IU/ml (Roche Molecular Systems) were utilized for
conﬁrmation of lack of viremia.
Spontaneous control of HCV was deﬁned as less than 600
IU/ml on two consecutive plasma specimens in the absence of
anti-HCV treatment and conﬁrmed as less than 60 IU/ml by
qualitative assay in 43 of 47 controllers of HCV in whom
sufﬁcient sample was available for retesting. Longitudinal
viral RNA titers were obtained at 60–180 d intervals after ﬁrst
documentation of control of HCV; sustained control of HCV
was deﬁned as negative for all subsequent time points,
including at least one conﬁrmation by qualitative assay,
whereas HCV recurrence was deﬁned as previous sponta-
neous HCV control with subsequent viremia on consecutive
time points, including both possibilities of recrudescent
infection (return of original infecting virus) or reinfection
(new infection). The timing of recurrence was calculated as
the point halfway between the last negative measurement and
the ﬁrst positive measurement.
Peptides and Recombinant Antigens
Recombinant protein HIV p24 (Protein Sciences [http://
www.proteinsciences.com]) and CMV viral lysate (BioWhit-
taker [http://www.cambrex.com]) were obtained commercially
with appropriate controls. HCV proteins were expressed as
carboxy-terminal fusion proteins with human superoxide
dismutase in Saccharomyces cerevisiae or Escherichia coli (Chiron
[http://www.chiron.com]). Individual proteins were derived
from the HCV-1 sequence and encoded core (c22–3 aa 2–
120), NS3 (c33c aa 1192–1457), NS4 (C100.3 aa 1569–1931),
and NS5 (aa 2054–2995). Two overlapping peptide sets
corresponding to the HCV-1 and HCV-H77 1a full HCV
genomes were also utilized as described previously [9,13].
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Lymphoproliferative (LP) assays were performed as pre-
viously described using designated viral antigens and corre-
sponding controls (superoxide dismutase, E. coli, or the
baculovirus-derived control mgs) at concentrations of 10 lg/
ml [13,15,21]. Fresh peripheral blood mononuclear cells
(PBMCs) were isolated from blood obtained in heparin,
trisodium citrate, citric acid, or dextrose tubes by Ficoll-
Hypaque density gradient centrifugation and plated at
100,000 cells/well in 96-well U-bottom plates (Costar [http://
www.costar.com]) in 200 ll of R10/Hab medium (i.e., RPMI
1640, 10% human antibody serum; both Sigma-Aldrich
[http://www.sigmaaldrich.com]) and 10 mM HEPES buffer
(Sigma-Aldrich) with 2 mM glutamine and antibiotics
(penicillin and streptomycin, 50 U/ml). Each protein and
each corresponding control was placed in quadruplicate wells
for each assay. After 6 d at 37 8C and 5% CO2, wells were
pulsed for 6 h with 1.0 lCi of
3H thymidine (NEN [http://las.
perkinelmer.com]). Cells were collected on ﬁlters, and
incorporated radiolabel was measured with a beta counter
(Packard Topcount, Packard Instruments [http://las.
perkinelmer.com]).
The stimulation index (SI) was deﬁned as the ratio of the
mean counts per min of the antigen wells to the mean
counts per minute of the control protein wells. For the
purposes of data interpretation, SI of ﬁve or more was
considered signiﬁcant [13,15,21]. For cross-sectional analysis,
the ﬁrst time point tested was utilized. Only assays with a
positive response to the phytohemagglutinin control were
included.
Antigen-Stimulated Cell Lines
Virus-speciﬁc CD4
þ T cell lines were generated via
stimulation of fresh PBMCs with R10 medium supplemented
with recombinant IL-2 (50 U/ml) and the respective recombi-
nant HCV antigen (1 lg/ml) [13,14] or by the appropriate
peptide as previously described [9,22]. These cell lines were
tested two to four weeks after stimulation.
Enzyme-Linked Immunospot for Single-Cell Quantification
of IFN-c Secretion
Enzyme-linked immunospot (ELISPOT) assays were per-
formed exactly as previously described [9]. Whether a speciﬁc
response was CD8
þ or CD4
þ was determined by depletion
using magnetic beads and columns according to the
manufacturer’s instructions (Miltenyi Biotec [http://www.
miltenyibiotec.com]) and/or testing by ELISPOT and intra-
cellular cytokine staining on short-term cell lines in the
presence of IL-2.
Statistical Analysis
Fisher’s exact test was used for comparison of proportions.
For cross-sectional analyses, nonparametric comparisons
were used for intergroup comparisons, and Spearman
correlations or linear regressions performed for determining
the relationship between continuous variables and immuno-
logic parameters. Kaplan-Meier analysis was used to describe
times to viral recurrence, difference between groups com-
pared by the log rank test; data were censored at the last
available time point. The degree of control of viremia was
calculated as area under the curve during the year following
recurrence. Graphical representations and statistical analyses
were performed using Microsoft Excel and GraphPad Prism
3.0 (GraphPad Software [http://www.graphpad.com]).
Results
Clinical Characteristics of Participants Exhibiting
Spontaneous Control of HCV
To deﬁne the impact of superimposed HIV infection on
the ability to control HCV viremia, we established four
groups of participants, all HCV antibody positive. Those with
HCV monoinfection were divided into those who have
persistent viremia and those who spontaneously control
viremia without anti-HCV therapy. Similarly, those coin-
fected with HIV were divided between one group consisting
of individuals with persistent HCV viremia and another
group exhibiting spontaneous control of HCV. Summary
clinical data regarding all patient groups are presented in
Table 1.
When comparing participants who spontaneously control
HCV with those who do not, there were no signiﬁcant
differences in demographic parameters such as age, race, or
sex. The only clinical, demographic, or laboratory parameter
associated with HCV spontaneous control was normal alanine
aminotransferase levels (Table 1, p¼0.001). In dually infected
persons with and without HCV viremia, there were no
differences in CD4
þ count or antiretroviral use. A decrease
in HIV viral loads (VLs) was detected in HIVþ persons with
spontaneous HCV control, although it did not reach
statistical signiﬁcance (median HIV VL, HCV chronic,
12,300 copies/ml; HCV controller 361 copies/ml; p ¼ 0.36,
Fisher’s exact test). We found a similar proportion of persons
who control HIV-1 (deﬁned as , 1,000 copies/ml in the
absence of antiretroviral treatment) in the HCV viremic and
HCV aviremic groups, indicating that spontaneous control of
HCV in this cohort did not correlate with control of HIV-1
within the same individual, although larger studies with
greater power are needed to address this relationship.
Multispecific CD4
þ LP Responses are Linked to
Spontaneous Control of HCV in HIVþ Persons
CD4
þ T cell responsiveness in these groups, subdivided by
HIV-1 status and HCV VL, was compared using a 2 3 2
factorial design. We compared HCV-speciﬁc CD4
þ LP
responses between monoinfected and coinfected partici-
pants, since these responses correlate with successful im-
munity against HCV [1,4,12]. In monoinfected participants,
spontaneous control of HCV was strongly associated with
proliferative responses (HCV controller, 12 of 14 [86%],
versus HCV viremic, 4 of 17 [24%]; p ¼ 0.003, Fisher’s exact
test) (Figure 1), a ﬁnding consistent with prior studies
[4,12,13]. In the presence of dual infection with HIV, HCV-
speciﬁc responses were enriched in HCV spontaneous
controllers, but HIV had a clear deleterious effect in that a
signiﬁcantly smaller percentage of persons had these re-
sponses when compared to those with monoinfection (HIV-1/
HCV controllers, 9 of 26 [35%], versus HIVþ/HCVþchronics,
2 of 30 [7%]; p¼0.016, Fisher’s exact test) (Figures 1 and 2). In
both HIVþ and HIV  controllers of HCV, responses against
HCV were often multispeciﬁc within single individuals (16 of
21 positive assays among HCV controllers, unpublished data).
We next examined whether the lack of responsiveness to
HCV antigens in the viremic group was due to a speciﬁc
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general inhibition of CD4
þ lymphoproliferation. The cumu-
lative SI to HCV antigens was signiﬁcantly higher in those
with spontaneous control of HCV (p ¼ 0.004; Mann-Whitney)
(Figure 3A); noting that fresh cells were not available to test
seven participants in the overall cohort. In coinfected
participants, we examined LP responses to HIV p24 and
CMV, limiting our analysis to participants seropositive for
each respective infection. We detected no abrogation of
responses to either p24 or CMV in the HCV viremic group
compared to those with HCV control (HIV, p¼0.32; CMV, p¼
0.58; Mann-Whitney) (Figure 3B and 3C). There was also no
signiﬁcant difference between responses to phytohemagglu-
tinin between the two groups (unpublished data). In
participants not on antiretroviral therapy, LP responses to
p24 antigen inversely correlated with HIV VLs (n ¼ 18, r ¼
 0.72, p   0.001, Spearman) consistent with prior studies
[21,23,24]. These data suggest that HCV viremia is associated
with a selective loss or impairment of HCV-speciﬁc CD4
þ T
cells rather than a global impairment of T cell proliferation
to other stimuli.
A Higher Nadir CD4
þ T Cell Count Correlates with
Preserved HCV-Specific CD4
þ T Cell Responses against
HCV in Dually Infected Participants
S i n c et h ea b o v ed a t ai n d i c a t et h a tH C V - s p e c i ﬁ cL P
responses are less frequently detected in persons dually
infected with HIV-1, we investigated whether contempora-
neous or historical nadir CD4
þ T cell counts were predictive
of LP responses against HCV in HIV-1-coinfected persons
with control of HCV. Since the primary pathogenic outcome
of HIV-1 infection is progressive loss of CD4
þ T cells, both
contemporaneous and historical nadir T cell counts are
potential predictors of LP responses against HCV in this
subgroup. HCV-speciﬁc CD4
þ LP responses were strongly
correlated with nadir CD4
þ counts but not with contempora-
neous counts for each HCV antigen (Table 2). Responses
against HIV p24 antigen followed a similar pattern as HCV, in
contrast to responses against CMV and responses following
stimulation with phytohemagglutinin, which showed no
signiﬁcant correlation (Table 2). When participants with a
history of either earlier treatment (nadir CD4
þ T cell count
.300) or long-term spontaneous control of HIV were
Table 1. Characteristics of 94 HCV-Infected Patients
Characteristic HIV-Negative HIV-Positive
HCV VL-Positive
(n ¼ 17)
HCV VL-Negative
(n ¼ 17)
HCV VL-Positive
(n ¼ 30)
HCV VL-Negative
(n ¼ 30)
% IVDU 68% 67% 87% 67%
Prior interferon None None None None
Age, y, mean (range) 45 (19–59) 46 (30–69) 44 (33–56) 44 (32–54)
Sex, % male 76% 59% 73% 63%
Race, % of European descent 82% 100% 77% 67%
Median HCV VL, IU/ml
a,b (interquartile range) 427,000 (141,000–807,000) ,60 2,250,000 (464,000–18,600,000) ,60
Mean ALT, IU/l (range)
b 70 (19–126) 22 (4–54) 64 (5–289) 36 (14–96)
CD4
þ/ll NA NA 578 (61–1343) 534 (4–1430)
Nadir CD4
þ/ll
c NA NA 309 (2–672) 228 (2–786)
ART status NA NA 16/30 (53%) 17/30 (56%)
Median HIV-1 VL, copies/ml
d NA NA 12,300 361
HIV-1 VL ,50 copies/ml (%) NA NA 12/30 (40%) 13/30 (43%)
LTNP of HIV-1 (%)
e NA NA 3/30 (10%) 6/30 (20%)
Cutoff for significance p , 0.05, two-tailed.
a Significant difference between columns one and three.
b Significant difference between columns one and three (RNA .600) and two and four (RNA  600).
c Nadir CD4 count data were unavailable for six of 60 participants with HIV-1.
d Difference in HIV VLs not significant between groups three and four (p ¼ 0.36).
e Long-term nonprogressor (LTNP) of HIV-1 defined as CD4
þ T cell count of . 500/ml and HIV-1 viral load of , 1,000 copies/ml for at least 5 y in the absence of antiretroviral therapy.
ALT, alanine aminotransferase; ART, antiretroviral therapy; NA, not applicable.
doi:10.1371/journal.pmed.0030492.t001
Figure 1. Rate of Detection of LP Responses against HCV Antigens by
Subgroup, Stratified by HIV Status and HCV Viremia
p-Values represent comparison of proportions per Fisher’s exact test.
HIV  persons with spontaneous control of viremia had the highest rate
of detection (86%). By comparison, HIVþ persons with spontaneous
control of viremia exhibited a 35% rate of LP responses. Both groups of
controllers demonstrated significantly higher rates of detection than did
their viremic counterparts. Fresh cells were not available for analysis of
four of 30 HIV-1/HCV controllers.
doi:10.1371/journal.pmed.0030492.g001
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HIV, T Cell Responses, and HCV Controlcombined (Figure 4), HCV-speciﬁc responses resembled the
HCV monoinfected controllers in terms of breadth and
magnitude.
We also performed parallel assays in the presence of the
antiretroviral drug zidovudine in vitro (0.5 lM) and after
CD8
þ T cell depletion with magnetic beads and were unable
to enhance our detection of LP responses against HCV
(unpublished data). These results suggest that the relative
paucity of proliferating HCV-speciﬁc CD4
þ T cells in HIVþ
persons who maintain HCV control is not due to HIV-1
replication in the culture or to CD8-mediated suppressive
effects.
Relationship of HCV-Specific CD4
þ LP Responses to IFN-c
T Cell Responses
Having demonstrated that dual infection with HIV is
associated with lower frequencies of HCV-speciﬁc CD4
þ T
cell responses, we determined whether this effect has an
impact on the magnitude of HCV-speciﬁc CD8
þ T cell
responses. The ex vivo CD8
þ IFN-c response to a compre-
hensive panel of antigens at the same time point was
determined by overnight ELISpot, using methods as previ-
ously described [9]. IFN-c-producing CD8
þT cells were found
to be present at higher magnitudes in those with CD4
þ LP
responses (p ¼ 0.0014, Mann-Whitney) (Figure 5).
Recurrence of HCV Viremia in HIVþParticipants with Prior
Control of HCV
Recurrence of viremia following clearance of HCV in-
fection has been reported in monoinfected persons who
previously cleared viremia spontaneously [25,26]. We exam-
ined the durability of viral control in participants with
spontaneous HCV control with and without HIV-1. We
obtained repeat HCV viral RNA testing at 60–180 d intervals
in 25 individuals (median length of follow-up was 438 d, range
121–932). A total of 19 coinfected participants maintained
undetectable HCV RNA, but six experienced recurrent
viremia (Table 3). Repeat viral RNA testing of 16 HIV-1-
negative HCV controllers revealed no instances of recurrent
viremia despite a similar number of measurements and
lengths of follow-up (median follow-up 518 d, range 361–
2,047 d). By Kaplan-Meier analysis, recurrent viremia was
more likely to occur in the HIV-1-positive group, suggesting
that those with HIV coinfection are at risk for these events (p
¼ 0.03, log rank test) (Figure 6). Comparing responses, we
detected a trend towards lower magnitude (cumulative SI to
all HCV antigens) of LP responses in those who experienced
recurrence versus all controllers who did not (p¼0.08, Mann-
Whitney).
Lack of samples from the acute phase of infection and
inability to sequence virus from periods of viral control
prevented determination of whether recurrent viremia
represented loss of intrinsic control of virus, which might
have been facilitated by the diminished HCV-speciﬁc CD4
þ
proliferative responses associated with HIV-1 or reinfection
with a novel strain [25]. Results of serotyping experiments on
plasma from these episodes of recurrence did not reveal
evidence of infection with more than one genotype that
would implicate reinfection as the primary mechanism (Table
3). None of the six individuals reported ongoing high-risk
behavior, especially active intravenous drug use, the most
efﬁcient method of transmission to support the latter
hypothesis. Two of the six participants were never intra-
venous drug users (IDUs) (routes of transmission were sexual
and related to blood products); the other four were former
IDUs.
Figure 3. HCV Viremia Is Associated with Decreased Lymphoproliferation against HCV Antigens But Not against HIV or CMV
(A) The cumulative SI against HCV antigens core, NS3, NS4, and NS5. Four of 60 coinfected participants and three of 34 monoinfected participants could
not be tested due to lack of fresh PBMCs, thus 87 of 94 of the total cohort were tested.
(B) Responses against HIV-1 p24 antigen. Of 60 coinfected participants, 53 were tested.
(C) Responses against CMV in coinfected participants, including the 42 participants confirmed as seropositive for CMV.
doi:10.1371/journal.pmed.0030492.g003
Figure 2. LP Responses to HCV Antigens Are Associated with
Spontaneous Control of Viremia Regardless of HIV Status
Stimulation indices to HCV proteins are plotted per subgroup. The two
plots on the left represent responses in HIV  persons; the two on the
right in HIVþ. Cutoff of significance for lymphoproliferation was an SI of
5, shown by horizontal dotted line. Median values are also shown.
doi:10.1371/journal.pmed.0030492.g002
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Viral Recurrence
We next examined the clinical outcomes of these six
recurrences of HCV viremia in HIV-1-infected individuals
with prior control of HCV. None of six participants who
experienced recurrence regained sustained control of HCV;
instead, persistent viremia was established in each case.
Furthermore, none of the six participants had symptoms
consistent with acute illness at the time of viral recurrence,
and only three of the six participants experienced signiﬁcant
(.3 3 upper limit of normal range) elevations in alanine
aminotransferase (Table 3). Wide ranges of HCV viral RNA
titers were observed following recurrence (HCV RNA range,
141–1.8 3 10
7 IU/ml) (Table 3).
We also examined the relationship between immune status
and magnitude of HCV viremia following recurrence.
Although the number of study participants is small, we
observed that the CD4
þ T cell count at time of breakthrough
negatively correlated with the calculated area-under-the-
curve of viremia (r¼ 0.943, p¼0.017, Spearman). These data
suggest that general immune status and/or HCV-speciﬁc
immunity have an impact on subsequent viral control after
recurrence.
For ﬁve participants (02–18, 03–27, 02Q, 03–29, and 01–23),
we quantiﬁed T cell responses before and after recurrence. In
participants 02–18 and 03–27, CD4
þ LP responses against
HCV overall declined following recurrence (data for 02–18
shown in Figure 7A) (Table 3). In participants 02–18, 03–27,
and 02Q, who demonstrated signiﬁcant preexisting CD8
þ
IFN-c responses and lower degree of viremia following
recurrence (Table 3), the magnitude of HCV-speciﬁc CD8þ
T cell responses over time declined, in contrast to a response
to an immunodominant Epstein–Barr virus epitope (Figure
7B–7D). By contrast, when we analyzed two participants with
very high levels of viremia following recurrence (Table 3),
participant 01–23 exhibited no detectable ex vivo ELISpot
response prior to or following viral recurrence (unpublished
data). Participant 03–29 had no detectable response by either
LP or ELISpot measurement prior to viral recurrence, and we
measured a single weak CD8
þ T cell response (50 spot-
forming cells/10
6 PBMCs) at the cutoff for signiﬁcance at only
one of ﬁve time points following recurrence (Figure 7E).
Table 2. LP Responses to HCV Antigens in HIVþHCV Controllers
Correlate More Strongly with Historical Nadir CD4
þ T Cell Counts
Than with Contemporaneous CD4
þ T Cell Counts
Antigen Nadir CD4 Current CD4
r
2 p-Value r
2 p-Value
Cumulative SI 0.45 0.0006 0.08 0.1568
Core 0.38 0.0024 0.03 0.3627
NS3 0.33 0.0055 0.12 0.0801
NS4 0.37 0.0026 0.08 0.1609
NS5 0.50 0.0002 0.05 0.2948
CMV 0.11 0.2179 0.03 0.4529
p24 0.42 0.0027 0.08 0.1954
PHA 0.01 0.6804 0.12 0.0777
r
2-Values represent Spearman correlation coefficients. For all HCV antigens a higher nadir
CD4
þT cell count represented a better correlate than current CD4
þT cell count with HCV-
specific CD4
þ T cell proliferative responses.
doi:10.1371/journal.pmed.0030492.t002
Figure 4. LP Responses in HIVþ Participants Who Spontaneously Control HCV
No participant with a history of CD4
þT cell depletion (nadir CD4 , 300 cell/ll) displayed LP response to HCV antigens (A), contrasting with responses to
CMV in which responses were detected in individuals with a history of significant CD4
þ T cell depletion (B). Those marked with * are CMV , and values
are therefore not shown
doi:10.1371/journal.pmed.0030492.g004
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þ T cell lines were expanded easily
from time points of viral control in two of these participants,
following recurrent viremia we were unable to expand cells
despite IL-2 supplementation, either by using individual
peptides corresponding with previously known CD4 speciﬁc-
ities or by whole antigen stimulation (unpublished data). In
summary, individuals with higher CD4
þ T cell counts, and
therefore preserved immunity, exhibited lower levels of HCV
viremia following recurrence, and the shift from controlled
to chronic HCV viremia was associated with attenuation of
circulating immune responses.
Discussion
Although spontaneous control of HCV infection is asso-
ciated with long-lasting cell-mediated immune responses
[3,4,13,23] and with partial protection following rechallenge
[25], the role of cell-mediated immune responses and their
relation to durability of control in the context of HIV
infection remain unclear. Here we analyzed the impact of
HIV infection on this apparent immune control in persons
who spontaneously control HCV infection with coexisting
HIV. We show that CD4
þT cell depletion induced by HIV-1 is
associated with loss of adaptive HCV-speciﬁc immune
responses. In addition, our ﬁndings indicate that: (1) HIV-
infected individuals with spontaneous control of HCV
maintained vigorous CD4
þ T cell responses against HCV, if
they exhibited higher nadir CD4
þ T cell counts; (2) additional
episodes of HCV viremia occur frequently in HIVþ partic-
ipants relative to their HIV counterparts; (3) preservation of
higher CD4
þ T cell counts, and therefore HCV immunity, is
potentially relevant to subsequent HCV viral RNA levels
following recurrence.
In HCV monoinfection, the vast majority of participants
who spontaneously control HCV generate [27] and maintain
[1,4,12,13] vigorous peripheral LP responses to HCV antigens.
Our previous study in 17 HIV-1/HCV-coinfected individuals
found no LP responses against HCV [15], consistent with
studies indicating that HCV-speciﬁc CD4
þ T cell responses
are absent or at strikingly low frequency in the setting of
HIV-1 coinfection [17,20,28]. However, by focusing on HIV/
HCV-coinfected individuals who demonstrated spontaneous
control of HCV, we identiﬁed certain HIV-1-infected
individuals with preserved circulating HCV-speciﬁc CD4
þ T
cells. In these individuals, CD4
þ lymphocytes target multiple
proteins and speciﬁcities as has been shown for the
monoinfected population [13,14]. Maintenance of higher
CD4
þT cell counts, either through long-term nonprogression
of HIV or through antiretroviral treatment before CD4
þ T
cell counts fell below ;300 cells per microliter, was the most
important shared feature of these individuals. Conversely, we
observed that participants with low nadir CD4
þ T cell counts,
b u ts i g n i ﬁ c a n ti m m u n er e c o n s t i t u t i o no na n t i r e t r o v i r a l
therapy, did not recover HCV-speciﬁc CD4
þ LP responses,
accounting for why nadir was a better predictor than
contemporaneous CD4
þ T cell count. Since we did not detect
HCV responses in those with nadir CD4
þ T cell counts below
300, in contrast to those against CMV, our data suggest that
the threshold CD4
þ T cell count that results in loss of
adaptive responses may be higher for HCV-speciﬁc responses
than those to CMV [29]. As a corollary, these data suggest that
treatment of HIV infection before advanced immunosup-
pression may preserve memory T cell responses against HCV.
Table 3. Clinical Data and Outcomes of Six HCV Recurrences in HIVþ Persons with Prior Control of HCV
Participant Time (d)
a Prior to Recurrence After Recurrence
CD4
b CD8 IFN-c CD4 LPA ALT Peak ALT Peak HCV RNA AUC (HCV RNA)
b CD4 LPA Serotyping
c
01–23 181 190 0 ND 12 590 13,980,000 1.30 3 10
9 Negative 1
02–10 155 302 0 ND 9 33 18,100,000 5.92 3 10
8 Negative Failed
03–29 238 321 0 Negative 42 343 11,200,000 1.20 3 10
8 Negative 1
02Q 568 885 180 Negative 37 49 49,300 1,471,000 Negative 4
02–18 500 639 1055 Positive 54 96 232,000 4,290,000 Negative 1
03–27 225 906 625 Positive 40 144 97,800 1,848,000 Negative 1
IFN-c response measurement units: spot-forming cell/10
6 PBMCs.
aNumber of days of documented spontaneous control. Actual duration may be longer as this did not include time prior to study period.
bArea under the curve of HCV viremia 1 y after recurrence, correlated with CD4 count (Spearman, r ¼  0.943, p ¼ 0.017).
cGenotype was detected by serology. No serotyping result demonstrated multiple genotypic infection.
ALT, alanine aminotransferase; AUC, area-under-the-curve; LPA, lymphoproliferative assay; ND, not done.
doi:10.1371/journal.pmed.0030492.t003
Figure 5. Relationship of CD4
þ T cell Proliferation against HCV Antigens
to CD8
þ IFN-c Responses
Total CD8
þ IFN-c response was determined via a comprehensive ELISpot
assay against the entire HCV-expressed polyprotein. In HIVþparticipants
who control HCV spontaneously, the magnitude of IFN-c responses
mediated by CD8
þ T cells is significantly higher in participants with LP
responses against HCV (p ¼ 0.0014, Wilcoxon rank-sum test).
doi:10.1371/journal.pmed.0030492.g005
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HIV, T Cell Responses, and HCV ControlWhat, then, is the importance of maintaining these
responses? HCV-speciﬁc CD4
þ T cell responses may confer
beneﬁts, as they may or may not be associated with improved
liver histology in chronically infected participants [20] and
are a crucial component of protective immunity upon
rechallenge in the chimpanzee model, by playing a key role
in supporting the pool of circulating functional CD8þT cells
[7]. Our study was not designed to examine the former
concept but provides evidence that supports the latter, as the
viral RNA levels observed in our coinfected participants with
recurrence were much higher than those from the earlier
study of high-risk IDUs [25].
Our results also show a high incidence (24%) of recurrent
HCV viremia in HIV-1-coinfected participants with initial
control of HCV, even in some who had previously maintained
HCV control for almost two years of observation. Whether
the cases of recurrent HCV viremia described in this report
are due to recrudescence of initially controlled virus [26,30]
or reinfection with a newly acquired strain remains unan-
swered by the present study. Loss of control of HCV viremia
has been described in both chimpanzee and human models
within the year following acute infection [1,3], however, the
six participants in the present study experienced recurrent
viremia long after the acute phase. In addition, our interviews
of participants and providers indicate a lack of active risk
factors for new exposure to virus, although we cannot rule
out this possibility deﬁnitively due to the potential of
underreporting of these risk factors and/or susceptibility to
other means of HCV transmission.
Regardless of whether our cases represent reinfection or
recrudescence, loss of adaptive immunity and susceptibility
to recurrent viremia provide potential explanations why HIV
coinfection abrogates protective immunity to HCV and is
associated with a higher rate of persistent HCV [31,32]. In
most coinfected patients, HCV infection precedes HIV
infection due to its greater transmissibility by blood, and
the outcome of HCV should be determined prior to
acquisition of HIV. Unlike the reinfections detected in those
with history of prior viral control in the study by Mehta and
colleagues [25], none of our participants with HCV recur-
rence were able to reestablish control, and those with the
least immunity established extremely high levels of HCV
viremia. Although limited by sample size, our data indicate
that the level of preserved immunity prior to recurrence has
an impact on the subsequent degree of HCV viremia
following a second challenge to the immune system,
consistent with ﬁndings from chimpanzee studies [7,33] and
with the concept of secondary immunity against HCV [25].
This study highlights the need for repeat HCV RNA testing
for persons with prior spontaneous control and suggests that
HIV-1 is a cofactor for recurrent HCV viremia [34]. The
clinical relevance of the observed viral recurrences remains
unclear, but the shift from sustained control to chronicity
likely confers risk of liver disease progression, which is
accelerated in HIV-1-infected persons [5]. Moreover, our
cross-sectional and longitudinal data extend other studies in
monoinfection that show that HCV chronicity is associated
with an attenuation of speciﬁc responses in the periphery
[4,12,13]. This decline of responses may have preceded HCV
viremia; alternatively, persistent HCV viremia may have
altered HCV-speciﬁc responses through chronic antigenic
stimulation.
In both our cross-sectional and longitudinal studies, the
high circulating viral titers of HCV in persistently viremic
individuals were not associated with a global change in
responses against other herpes viruses, indicating that HCV
viremia is associated with a lack of HCV-speciﬁc CD4
þ T cells
but does not signiﬁcantly inhibit CD4
þ T cell proliferation to
other viral antigens. The decrement of functional responses
in the presence of viremia may be due to a variety of
mechanisms, including viral escape, T cell deletion or
exhaustion, and compartmentalization. The hypothesis that
loss of virus-speciﬁc CD4
þ T cell responses associated with
chronic HCV infection results in loss of CD8
þT cell responses
and viral escape [7] deserves further study in coinfected
humans. Also, while proliferative capacity is a strong
correlate of viral control, it has been suggested that other
functions of T cells may not correlate with proliferation
[35,36]; therefore, further detailed characterization of these
cells should elucidate further mechanisms of loss of viral
control. Finally, we provide support of the concept that
therapeutic vaccines or immunotherapies that successfully
restore the frequencies and function of HCV-speciﬁc CD4
þ T
cell responses in chronically infected individuals may result
in improved control. This may be particularly important in
individuals dually infected with HIV-1, whose high HCV titers
interfere with efﬁcacy of interferon-based treatments [37].
In summary, we provide a detailed analysis of HCV-speciﬁc
CD4
þ T cells in the unique setting of HIV-1-infected
participants with spontaneous control of HCV. T cell
responses against HCV are preserved by avoiding CD4
þ T
cell depletion due to progressive HIV-1 infection, indicating
a potential immunologic beneﬁt of treatment of HIV in
coinfected individuals before CD4
þ T cell counts fall below
300 cells per microliter, a threshold at the higher end of the
current range where initiation of treatment is typically
recommended. The importance of preserving these adaptive
immune responses is implied by: (1) the observed loss of
control of HCV only among HIV-1-infected individuals with
prior clearance of HCV and not in HIV  counterparts; and
(2) their relevance to intrinsic control of HCV following
rechallenge. Further understanding of the immune correlates
of maintaining natural HCV control and subsequent loss of
Figure 6. Recurrent Viremia in Persons with Evidence of Spontaneous
Control of HCV
Serial HCV VL determinations were performed in persons demonstrating
spontaneous control of HCV. Data were censored at the last available
time point. Six of 25 participants experienced recurrent HCV viremia in
the HIVþgroup, while 0 of 16 HIV participants experienced recurrence.
The median time of follow-up did not differ between groups.
doi:10.1371/journal.pmed.0030492.g006
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HIV, T Cell Responses, and HCV Controlcontrol will enhance our knowledge of the quality and
quantity of CD4
þ and CD8
þ T cell responses necessary to
elicit long-lasting and cross-protective immunity.
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Figure 7. HCV-Specific T Cell Responses before and after HCV Recurrence in HIVþ Participants with Prior Spontaneous Control
(A) LP responses before and after HCV recurrence. Responses to c33c (NS3) and NS5 declined after the establishment of viremia. By contrast, stimulation
indices to HIV-1 p24 antigen and phytohemagglutinin (positive control) increased.
(B–E) The degree of viremia is shown in shaded gray for four participants. IFN-c measurements are in spot-forming cell (SFC)/10
6 PBMCs. The cumulative
HCV CD8
þ T cell response is represented by the solid red lines. In three participants who demonstrated decline in HCV-specific CD8
þ T cell responses,
Epstein–Barr virus (EBV) response to the lytic A2 epitope (GLCTLVAML) is shown by the blue dashed lines.
doi:10.1371/journal.pmed.0030492.g007
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Background. Because of shared transmission routes (contaminated
needles, contaminated blood products, and, to a lesser extent,
unprotected sex), a large proportion of HIV-infected individuals
(estimates range between 25% and 33%) are also infected with the
hepatitis C virus (HCV). In most but not all individuals infected with HCV,
the virus infection is chronic and causes liver disease that can eventually
lead to liver failure. Disease progress is slow; it often takes decades until
infected individuals develop serious liver disease. In people infected with
both HCV and HIV, however, liver disease caused by HCV often appears
sooner and progresses faster. As highly active antiretroviral therapy
(HAART) and prophylaxis of opportunistic infections increase the life
span of persons living with HIV, HCV-related liver disease has become a
major cause of hospital admissions and deaths among HIV-infected
persons.
Why Was This Study Done? A sizable minority of people who are
infected with HCV manage to control the virus and never get liver
disease, and scientists have found that these people somehow mounted
a strong immune response against the hepatitis C virus. CD4
þT cells, the
very immune cells that are infected and destroyed by HIV, play an
important role in this immune response. The goal of the present study
was to better understand how infection with HIV compromises the
specific immune response to HCV and thereby the control of HCV
disease progression.
What Did the Researchers Do and Find? The researchers recruited four
groups of patients, 94 in total, all of whom were infected with HCV. Two
groups comprised patients who were infected with HIV as well as HCV,
with either high or undetectable levels of HCV (30 patients in each
group). The two other groups included patients not infected with HIV,
either with high or undetectable levels of HCV (17 patients in each
group). The researchers focused on the individuals who, despite
coinfection with HIV, were able to control their HCV infection. They
found that those individuals managed to maintain relatively high levels
of CD4
þ T cells that specifically recognize HCV. However, a quarter of
these patients (six out of 25) failed to keep HCV levels down for the
entire observation period of up to 2.5 years; their blood levels of HCV
rose substantially, most likely due to recurrence of the previously
suppressed virus (the researchers could not be certain that none of the
patients had become infected again after a new exposure to HCV-
contaminated blood, but there was no evidence that they had engaged
in risky behavior). The rise of HCV levels in the blood of the relapsed
patients coincided with a drop in overall CD4
þ T cell numbers. Following
relapse in these individuals, HCV did not return to undetectable levels
during the study. During the same period none of the 16 HIV-uninfected
people with controlled HCV infection experienced a recurrence of
detectable HCV.
What Do These Findings Mean? Despite the relatively small numbers of
patients, these results suggest that recurrence of HCV after initial control
of the virus is more likely in people who are coinfected with HIV, and that
HCV control is lost when CD4
þ T cell counts fall. This is one more reason
to test all HIV-positive patients for HCV coinfection. Coinfected patients,
even those who seem to be controlling HCV and would not automati-
cally receive HCV treatment, should be regularly tested for a rise of HCV
levels. In addition, maintaining CD4
þ T cells at a high level might be
particularly important for those patients, which means that doctors
might consider starting HAART therapy earlier than is generally
recommended for HIV-infected individuals. Additional studies are
needed to support these recommendations, however, especially as this
study did not follow the patients long enough to determine the
consequences of the observed loss of control of HCV.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030492.
  AIDS Treatment Data Network factsheet on HIV/HCV coinfection
  US CDC factsheet on HIV/HCV coinfection
  American Liver Foundation, information on HIV and HCV
  MedlinePlus pages on HCV
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